作者: Ehab Esmat Fawzy
DOI: 10.15406/JCPCR.2015.02.00057
关键词: Surgical oncology 、 Lung cancer 、 Medicine 、 Hyperthermic intraperitoneal chemotherapy 、 Oncology 、 Gynecologic oncology 、 Colorectal cancer 、 Cancer 、 Chemotherapy 、 Internal medicine 、 Epidemiology of cancer
摘要: Background: Management of peritoneal metastases from colorectal cancer is a highly debatable subject. Treatment options this disease range systemic chemotherapy, surgery followed by chemotherapy to resection, then and intraperitoneal with hyperthermia. Aim the study: To review guidelines updated studies on management carcinomatosis caused cancer. Methodology: The study includes systematic reviews, multi-institutional data collection, randomized controlled trials clinical reviews. Results: A total number 893 patients advanced colon who presented as stage IV first presentation have been involved in study. most significant finding these role either given neoadjuvant, adjuvant or combined modality. addition Bevazucimab vascular endothelial growth factor (VEGF) was improving response rate survival. use Mitomycin C (MMC) component HIPEC: hyperthermic chemotherapy) better than Oxaliplatinin terms median overall Conclusion: best treatment strategy for give neoadjuvant (no specific regime showed superiority over others) VEGF aiming at maximum cytoreduction, doing HIPEC using chemotherapeutic agent including Bevazicumab component.